By James O’Keefe’s Project Veritas has released a shocking new video wherein a Pfizer executive named Jordon Trishton Walker says that the gigantic pharma company has begun trying to “mutate” the COVID-19 virus through “Directed Evolution” as a way to create new vaccines in the future.
The videos have left everyone asking one question: What could go wrong?
BREAKING: @Pfizer Exploring "Mutating" COVID-19 Virus For New Vaccines
"Don't tell anyone this…There is a risk…have to be very controlled to make sure this virus you mutate doesn't create something…the way that the virus started in Wuhan, to be honest."#DirectedEvolution pic.twitter.com/xaRvlD5qTo
— Project Veritas (@Project_Veritas) January 26, 2023
“One of the things we’re exploring is like, why don’t we just mutate it [COVID] ourselves so we could create — preemptively develop new vaccines, right? So, we have to do that. If we’re gonna do that though, there’s a risk of like, as you could imagine — no one wants to be having a pharma company mutating f**king viruses,” Walker said to the Project Veritas reporter.
Walker: “Don’t tell anyone. Promise you won’t tell anyone. The way it [the experiment] would work is that we put the virus in monkeys, and we successively cause them to keep infecting each other, and we collect serial samples from them.”
Walker: “You have to be very controlled to make sure that this virus [COVID] that you mutate doesn’t create something that just goes everywhere. Which, I suspect, is the way that the virus started in Wuhan, to be honest. It makes no sense that this virus popped out of nowhere. It’s bullsh*t.”
Walker: “From what I’ve heard is they [Pfizer scientists] are optimizing it [COVID mutation process], but they’re going slow because everyone is very cautious — obviously they don’t want to accelerate it too much. I think they are also just trying to do it as an exploratory thing because you obviously don’t want to advertise that you are figuring out future mutations.”
In other parts of the video, Walker discusses how mutating viruses are “cash cows” for the company. The Post Millennial noted, “He answered, “Because some of the times there are mutations that pop up that we are not prepared for. Like with Delta and Omicron. And things like that. Who knows? Either way, it’s going to be a cash cow. COVID is going to be a cash cow for us for a while going forward. Like obviously.
“Well, I think the whole research of the viruses and mutating it, like, would be the ultimate cash cow,” the journalist replied, to which Walker acknowledged, “Yeah, it’d be perfect,” adding that Big Pharma “…is a revolving door for all government officials.”
He continued, “So, in the pharma industry, all the people who review our drugs — eventually most of them will come work for pharma companies. And in the military, defense government officials eventually work for defense companies afterwards.”
Walker noted that the practice was “…pretty good for the industry to be honest. It’s bad for everybody else in America.”
He continued, saying, “…when the regulators reviewing our drugs know that once they stop regulating, they are going to work for the company, they are not going to be as hard towards the company that’s going to give them a job.”
The video comes on the heels of an op-ed by socialist Senator Bernie Sanders in Fox News of all places.
The former presidential canididate writes, “There is a lot of discussion about how “divided” our nation is and, on many issues, that is absolutely true. But on one of the most important matters facing our country the American people – Democrats, Republicans, Independents, Progressives, Conservatives – could not be more united. And that is the need to take on the unprecedented corporate greed of the pharmaceutical industry and to substantially lower the outrageously high price of prescription drugs.
Today, millions of Americans are making the unacceptable choice between feeding their families or buying the medicine they need. Seniors from Vermont to Alaska are forced to split pills in half and many have died because they did not have enough money to fill their prescriptions.
Last year over 1 million Americans with diabetes had to ration insulin because they could not afford to take it as prescribed. Why? In large part because Eli Lilly, which made $5.6 billion in profits in 2021, increased the price of Humalog by 1,200% since 1996 to $275 while its CEO made nearly $50 million in compensation making him one of the highest-paid pharmaceutical CEOs in America. Humalog costs an estimated $8 to produce and can be purchased for about one-tenth the price in Canada.
Meanwhile, as Americans die because they cannot afford the medications they need, five of the largest drug companies in the U.S. made nearly $80 billion in profits last year (a 104% increase from the previous year) while the CEOs of just 13 pharmaceutical companies made over $1 billion in total compensation in 2021.
It does not have to be this way. The reality is that if Congress had the courage to take on the greed of the pharmaceutical industry, we could cut the price of prescription drugs in America by at least 50%. How? By preventing the pharmaceutical industry from charging more for prescription drugs in the U.S. than they do in Canada, Britain, Germany, France and Japan – a concept that is not only supported by progressives, but former President Donald Trump. I will soon be re-introducing legislation in the Senate to do just that.”
While Bernie and Trump might be on the same page, Republicans in the House and Senate have argued that the focus should be on the way drugs are marketed and priced in the commercial market.
Roll Call reported, “Factions of the health care system and members of Congress are turning their fire on an oft-maligned part of the drug pricing system — the middlemen who negotiate discounts with drug companies on behalf of health plans.
The business practices of pharmacy benefit managers, or PBMs, have attracted the ire of community pharmacies, health care providers, drug companies and both Republicans and Democrats, who argue the middlemen lead to increased costs for patients.
Sens. Maria Cantwell, D-Wash., and Charles E. Grassley, R-Iowa, plan to reintroduce legislation this year that would address many of the issues raised by PBM critics, including spread pricing, a practice in which PBMs charge payers like health plans and Medicaid more for a drug than what they reimburse to the pharmacy.
The bill would also prohibit PBMs from “clawing back” payments to pharmacies, a practice that community pharmacies argue has harmed their businesses, and require PBMs to file certain information with the Federal Trade Commission.”
Last year, the bill passed through the Senate’s Commerce, Science and Transportation Committee by a vote of 19-9. Six Republicans joined the Democrats to advance the bill, but Chuck Schumer did not let it see the floor for a vote, citing “scarce floor time” rather than the fact that the Majority Leader has “received more money from Big Pharma than any other Senator save one.”
[Read More: New WH Chief of Staff Has Hunter Connections]
